Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine in early-stage breast cancer with low-HR expression (CALORIE)
NCT03821454Unknown
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Feb 2019
- Primary completion
- Feb 2020
01
Overview
Randomised, double-blind trial in breast cancer comparing Capecitabine Arm with Placebo Arm (2 arms). Primary endpoints: Disease-Free Survival at 5 years and Overall Survival at 5 years. Status: unknown.
02
Drugs
capecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03821454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03821454.